Journal: bioRxiv

Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

doi: 10.64898/2026.02.17.706284

Figure Lengend Snippet: (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all NSCLC PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.

Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

Techniques: Viability Assay, Flow Cytometry, Clonogenic Assay, Control, Western Blot, Transfection, MANN-WHITNEY

Journal: bioRxiv

Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

doi: 10.64898/2026.02.17.706284

Figure Lengend Snippet: (a, b) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. (a) Left panels: representative immunoblots of the indicated proteins. GAPDH was used as a loading control. Right panels: densitometric quantification (fold change) of SF3B1, ATR or DNA-PKcs signal normalized to GAPDH signal. Mean ± SD. n=3. (b) RT-qPCR (fold change) of SF3B1 , ATR or PRKDC mRNA level. Mean ± SD. n = 3. (a, b) Mann-Whitney t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p<0.0001. (c) Correlation between SF3B1 and DNA-PKcs or ATR protein levels in a series of 77 NSCLC cell lines based on CCLE database. (d) Correlation between SF3B1 and PRKDC mRNA levels in lung adenocarcinoma patients retrieved from TCGA public database.

Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

Techniques: Transfection, Control, Western Blot, Quantitative RT-PCR, MANN-WHITNEY

Journal: bioRxiv

Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

doi: 10.64898/2026.02.17.706284

Figure Lengend Snippet: (a) Overall Rate Response (ORR) of all NSCLC PDXs (n = 25) treated with 4 mg/kg cisplatin, 5 mg/kg pladienolide B or a combination of both as compared to vehicle condition. Two-tails Mann-Whitney t test. ** p< 0.01, *** p< 0.001. (b) Probability of tumor progression (Relative Tumor Volume = 2) in control, pladienolide B-, cisplatin- or pladienolide B + cisplatin-treated PDXs. n = 7. Log-rank test. * p< 0.05, ** p < 0.01, *** p< 0.001. (c) LCF26 and ML1LC2 PDXs were treated with vehicle (ctrl), 4 mg/kg cisplatin, 5 mg/kg pladienolide B, or a combination of both. Left panels: immunoblots of DNA-PKCs and ATR. 3 PDXs/condition. GAPDH was used as a loading control. Right panels: normalized expression of DNA-PKcs or ATR according to GAPDH. Mann-Whitney t test. * p< 0.05, ** p< 0.01. (d) RT-PCR analysis of skipping of MLH3 -Ex8 in each PDX (3 distinct mice/PDX). Representative agarose gels of amplified products. Right numbers indicate amplicon size (in base pairs). Below numbers indicated the percentage of exon 8 exclusion. Mean ± SD.

Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

Techniques: MANN-WHITNEY, Control, Western Blot, Expressing, Reverse Transcription Polymerase Chain Reaction, Amplification

Journal: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Article Title: Release Kinetics of Paclitaxel and Cisplatin from Two and Three Layered Gold Nanoparticles

doi: 10.1016/j.ejpb.2015.02.017

Figure Lengend Snippet: Assessment of efficacy of drug-loaded Two and Three Layer Gold Nanoparticles in 3D cell culture with three non-small cell lung cancer (NSCLC) cell lines.

Article Snippet: Evaluation of Nanoparticle Efficacy Three human non-small cell lung cancer (NSCLC) cell lines, A-549, PC-9, NCI-H358, were maintained in RPMI 1640 medium (Cellgro, Corning Inc.) supplemented with 10% fetal bovine serum (Cellgro, Corning Inc.) and 1% penicillin-streptomycin-glutamine (Cellgro, Corning Inc.) in standard culture conditions.

Techniques: Cell Culture